Literature DB >> 8619591

In vitro antibacterial activity and beta-lactamase stability of a new carbapenem, BO-2727.

K Inoue1, Y Hamana, S Mitsuhashi.   

Abstract

The in vitro activity of BO-2727, a new carbapenem, was compared with those of meropenem, biapenem, imipenem, and ceftazidime. BO-2727 was four- or eightfold more active than the other carbapenems against methicillin-resistant staphylococci and Pseudomonas aeruginosa strains, including imipenem- and ceftazidime-resistant bacteria. BO-2727 was quite stable to penicillinases, cephalosporinases, and oxyiminocephalosporinases, but not to metallo-beta-lactamase. Time-kill studies against Staphylococcus aureus Smith, Escherichia coli ML4707, and P. aeruginosa GN11189 showed that BO-2727 has potent bactericidal activity at concentrations greater than the MIC.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8619591      PMCID： PMC162938          DOI： 10.1128/AAC.39.10.2331

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  A spectrophotometric assay of beta-lactamase action on penicillins.

Authors:  S G Waley
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

2.  In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.

Authors:  S Nakagawa; T Hashizume; K Matsuda; M Sanada; O Okamoto; H Fukatsu; N Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

3.  Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia.

Authors:  Y Saino; F Kobayashi; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

4.  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

Review 5.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

6.  In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria.

Authors:  S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

7.  Properties of novel beta-lactamase produced by Bacteroides fragilis.

Authors:  A Yotsuji; S Minami; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

8.  Biochemical properties of beta-lactamase produced by Flavobacterium odoratum.

Authors:  K Sato; T Fujii; R Okamoto; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

9.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

10.  Comparative stability of newly introduced beta-lactam antibiotics to renal dipeptidase.

Authors:  H Mikami; M Ogashiwa; Y Saino; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191
View more
  2 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.